

Index

¹¹¹In-octreotide, 140
¹¹¹In-oxine, 206
¹¹C Acetate PET, 126
¹¹C IMA107 binding, 7
123I-iofluopane SPECT, 2
¹²³I-mIBG, 142
¹⁷⁷Lu-DOTATATE, 147
¹⁸F-DOPA PET, 5
¹⁸F-FDG, 18, 25, 16, 61, 145, 210, 122
¹⁸F-PSMA PET, 125
⁶⁷Ga-CITRATE, 125, 126, 206
⁹⁹MTC, 125, 208, 209, 210

A

Adrenal metastases, 68
Anatomy, 160
Artificial intelligence, 29, 72

B

Benign thymic tumors, 85
Biliary tract cancers, 130
Bone metastases, 67
Brain metastases, 68
Breast Cancer, 63, 105
Breast-specific gamma imaging, 116
Brown adipose tissue, 25

C

Cholangiocarcinoma, 131
Consultation, 176
Contraindications, 148
Conventional imaging modalities, 107
Cross sectional imaging, 97
Current guidelines, 110

D

DaTScan, 2
Delayed imaging, 63
Diagnosis of breast carcinoma, 108
Differentiated adenocarcinoma, 61
Differentiated thyroid cancer, 46
Diffuse large B cell lymphoma, 95
Disease recurrence detection, 23
Dopaminergic, 2
Dosimetry, 181
Ductal carcinoma in situ, 108

E

Early prediction, 92
Ejaculatory duct, 161
Eligibility criteria, 147
Embryologic origin, 140
Essential tremor, 2
Ewing sarcoma, 199

F

FDG avidity, 64
FDG PET-CT, 5, 44, 159, 192
F-DOPA PET, 4
Fibroblast activation protein, 113
Follow-up, 23, 50, 91
Functional imaging, 44

G

Gallbladder carcinoma, 130
Gamma camera imaging, 115
Genitourinary pathology, 159
Germ cell tumors, 84, 200
Graves' disease, 38

H

Head and neck cancers, 15
Hepatic metastases, 128
Hepatobiliary cancers, 121
Hepatocellular carcinoma, 122
Heterogeneity, 64
Histopathological subtypes, 106
Hopkins criteria, 22
Hormone receptor targeted imaging, 111
Hounsfield units, 60
Hyperthyroidism, 38

I

Immunotherapy, 69
Infection, 205
Infusion method, 149
Initial staging, 91
Inoperable breast cancer, 108
Iron-sensitive magnetic
 resonance imaging, 8

J

Jaundice, 39

K

Ki-67, 62

L

Langerhans cell histiocytosis, 200
Liposarcoma, 76
Liver, 128
Liver-directed therapies, 145
Locoregional disease, 145
Lung cancer 64, 71
Lung tumors, 59
Lymphoma, 84, 191

M

M staging, 67
Magnetic resonance imaging, 2, 6
Magnetic resonance spectroscopy, 7
Malignant pleural mesothelioma, 73
Malignant thymic tumors, 86
Maxon method, 46
Mediastinal germ cell tumors, 90
Mediastinal tumors, 83
Medullary thyroid cancer, 53
Mesothelioma, 73
MIBG, 3, 4, 151, 196
Molecular imaging, 1
Multiple system atrophy, 2

N

N staging, 67
Nephroblastoma, 199
Neuroblastoma, 195
Neurodegenerative disease, 2
Neuroendocrine tumor, 87, 127, 139
Neuroimaging biomarkers, 2
NHL staging system, 193
Nigrostriatal dopamine, 2
NI-RADS PET/CECT, 22
NM-MRI and QSM images, 8
Non seminoma, 93
Non seminomatous germ cell
 tumors, 90
Nondopaminergic, 2
NON-F-18FDG PET/CT imaging, 111
Non-prostate, 159
Novel molecular imaging agents, 195
Novel PET molecular imaging agents, 26
Novel PET radiopharmaceuticals, 71
Novel targets, 115
Nuclear imaging, 37
Nuclear medicine, 43

O

Occult primary detection, 23
Osteosarcoma, 198
Outpatient instructions, 42, 51

P

Paragangliomas, 196
Parkinson's disease, 1
Parkinsonism, 2
Patient consent, 40, 47
Patient preparation, 149
Patient screening, 40, 46, 147
Patient selection, 176
PDE10 A PET scan, 6
Pediatric lymphoma, 187
Penile cancer, 161
PET/CT and CECT, 84
PET/MR imaging, 27
PET/MRI, 117
Pheochromocytoma, 196
PK11195 PET, 5
Pleural imaging, 77
Pleural lipoma, 76
Pleural metastases, 67, 76
Pleural tumors, 59, 73
Positron emission tomography, 2, 4
Post-chemotherapy
 residual disease, 92
Posterior mediastinal tumors, 94
Post-therapy scintigraphy, 181
Pretherapy screening, 48
Prognosis prediction, 25
Progressive supranuclear palsy, 2
Proliferation based imaging, 113
Prostate cancer, 171
Prostate specific membrane
 antigen, 172
PSMA PET imaging, 177

Q

Qualitative interpretation, 62
Quantitative variability, 85
Quinoline-based PET, 88

R

Radioiodine theranostics, 44
Radiomics, 72, 130
Radionuclide Therapy, 171
Radiopharmaceuticals, 64, 189, 207
Radiotherapy planning, 20
Radiotracers, 140
RAI therapy, 38, 46
Recurrence evaluation, 108, 125
Respiratory gating, 64
Response assessment, 69, 124
Response evaluation, 194
Response monitoring, 75
Response to therapy, 68
Retinoblastoma, 200
Rhabdomyosarcoma, 199

S

Sarcomas, 187, 195
SARCOMAS, 195
Seminal vesicle cancer, 163
Seminoma, 90, 92
Sentinel lymph node biopsy, 28, 116
Single-photon emission computed
 tomography, 2
Skeletal scintigraphy, 115
Solid tumors, 187, 195
Solitary pulmonary nodules, 60
Somatostatin analogs, 146
Somatostatin receptor-expressing
 tumors, 151
SPN calculator, 64
Squamous cell carcinoma, 64

SSTR2 PET analogues, 142
Staging, 17, 66, 108, 122
Surgical planning, 19
Surveillance, 70, 194
SUV max, 71

T

T staging, 66
TARE imaging, 125
Tc-99m sestamibi, 43
Testicular cancer, 164
Theranostics, 172
TheraP trial, 174
Therapy planning, 75
Thoracic neurogenic tumors, 94, 97
Thymic carcinoma, 87
Thymic cysts, 85
Thymic epithelial tumors, 86
Thymic hyperplasia, 85
Thymic tumors, 84
Thymolipoma, 86
Thymoma, 86
Thyroid cancers, 43, 44
Thyroid disorders, 37
Thyroid nodules, 43
Thyroiditis, 38
Timing of post-treatment, 68
Toxic multinodular goiter, 38
Transarterial radioembolization, 146
Treatment response, 21, 92
Tumor microenvironment targeted
imaging, 113

Tyrosine kinase receptor
targeted imaging, 113

U

Ultrasound, 116, 165
Uptake, 85
Urinary, 141, 160, 163, 164

V

Vascular invasion, 124
VISION trial, 174

W

Waldeyer's ring, 25
Washout index, 44
Whole body scintigraphy, 45
Wilms tumor, 199

X

X-ray beam, 26, 110

Y

Yttrium-90, 134

Z

Zebra diagnoses, 140
Zirconium-89, 113